TRDA
Entrada Therapeutics, Inc.
Price Chart
Latest Quote
$6.81
+0.31 (+4.77%)
Current Price
| Previous Close | $6.50 |
| Open | $6.54 |
| Day High | $7.06 |
| Day Low | $6.54 |
| Volume | 192,983 |
Stock Information
| Shares Outstanding | 38.82M |
| Total Debt | $49.75M |
| Cash Equivalents | $254.86M |
| Revenue | $5.74M |
| Net Income | $-166.12M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $264.37M |
| EPS (TTM) | $-4.00 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $29.11M |
| Sales | $5.74M |
| Income | $-166.12M |
| Book/sh | $8.50 |
| Cash/sh | $6.57 |
| Employees | 152 |
Financial Ratios
| Quick Ratio | 13.40 |
| Current Ratio | 13.90 |
| Debt/Eq | 18.37 |
Returns & Margins
| ROA | -26.84% |
| ROE | -48.28% |
| Operating Margin | -4834.63% |
Ownership
| Insider Ownership | 12.31% |
| Institutional Ownership | 78.39% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.09 |
| P/S | 46.07 |
| P/B | 0.80 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $18.75 |
Technical Indicators
| SMA20 | $6.54 |
| SMA50 | $9.63 |
| SMA200 | $9.43 |
| RSI | 49.85 |
| ATR | 0.4550 |
| Shares Float | 19.50M |
| Short Float | 6.91% |
| Short Ratio | 2.52 |
| Volatility | -0.26 |
| Rel Volume | 0.70 |
Performance History
| Week | +14.07% |
| Month | +15.62% |
| Quarter | -42.68% |
| 6 Months | -38.26% |
| YTD | -32.24% |
| Year | -8.10% |
| 3 Years | -56.09% |
| 10 Years | -71.57% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $6.81 | 201,200 |
| 2026-06-16 | $6.50 | 174,000 |
| 2026-06-15 | $6.57 | 192,400 |
| 2026-06-12 | $6.46 | 186,000 |
| 2026-06-11 | $6.31 | 339,800 |
| 2026-06-10 | $5.97 | 269,100 |
| 2026-06-09 | $6.37 | 175,800 |
| 2026-06-08 | $6.26 | 245,800 |
| 2026-06-05 | $6.37 | 195,000 |
| 2026-06-04 | $7.00 | 235,400 |
| 2026-06-03 | $6.58 | 240,500 |
| 2026-06-02 | $6.64 | 299,100 |
| 2026-06-01 | $6.91 | 280,700 |
| 2026-05-29 | $7.07 | 278,000 |
| 2026-05-28 | $6.82 | 307,500 |
| 2026-05-27 | $6.63 | 426,500 |
| 2026-05-26 | $6.70 | 513,500 |
| 2026-05-22 | $6.56 | 369,400 |
| 2026-05-21 | $6.31 | 372,000 |
| 2026-05-20 | $6.04 | 440,600 |
| 2026-05-19 | $5.65 | 378,200 |
| 2026-05-18 | $5.89 | 433,800 |
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
đ° Latest News
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
MarketBeat âĸ 2026-05-09T06:07:54Z
Entradaâs stock drops as DMD drugâs efficacy falls short
Clinical Trials Arena âĸ 2026-05-08T10:39:36Z
Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?
Investor's Business Daily âĸ 2026-05-07T20:04:07Z
Sector Update: Health Care Stocks Softer Late Afternoon
MT Newswires âĸ 2026-05-07T19:44:27ZEntrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-07T12:50:09Z
Entrada shares dive as Duchenne results disappoint
BioPharma Dive âĸ 2026-05-07T11:14:07Z
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
Zacks âĸ 2026-05-05T13:12:00Z
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-04T21:10:02Z
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
Motley Fool âĸ 2026-03-18T18:08:40Z
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
Motley Fool âĸ 2026-03-18T17:54:46Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $25,421,000 | $210,782,000 | $129,013,000 | $0 |
| Operating Revenue | $25,421,000 | $210,782,000 | $129,013,000 | $0 |
| Expenses | ||||
| Total Expenses | $183,319,000 | $163,771,000 | $132,175,000 | $97,248,000 |
| Net Non Operating Interest Income Expense | $15,072,000 | $19,474,000 | $15,218,000 | $2,632,000 |
| Operating Expense | $183,319,000 | $163,771,000 | $132,175,000 | $97,248,000 |
| General And Administrative Expense | $41,050,000 | $38,465,000 | $32,291,000 | $30,639,000 |
| Total Other Finance Cost | - | - | - | $-2,632,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-143,750,000 | $65,626,000 | $-6,685,000 | $-94,616,000 |
| Net Interest Income | $15,072,000 | $19,474,000 | $15,218,000 | $2,632,000 |
| Interest Income | $15,072,000 | $19,474,000 | $15,218,000 | $2,632,000 |
| Normalized Income | $-143,750,000 | $65,626,000 | $-6,685,000 | $-94,616,000 |
| Net Income From Continuing And Discontinued Operation | $-143,750,000 | $65,626,000 | $-6,685,000 | $-94,616,000 |
| Total Operating Income As Reported | $-157,898,000 | $47,011,000 | $-3,162,000 | $-97,248,000 |
| Net Income Common Stockholders | $-143,750,000 | $65,626,000 | $-6,685,000 | $-94,616,000 |
| Net Income | $-143,750,000 | $65,626,000 | $-6,685,000 | $-94,616,000 |
| Net Income Including Noncontrolling Interests | $-143,750,000 | $65,626,000 | $-6,685,000 | $-94,616,000 |
| Net Income Continuous Operations | $-143,750,000 | $65,626,000 | $-6,685,000 | $-94,616,000 |
| Pretax Income | $-142,826,000 | $66,485,000 | $12,056,000 | $-94,616,000 |
| Interest Income Non Operating | $15,072,000 | $19,474,000 | $15,218,000 | $2,632,000 |
| Operating Income | $-157,898,000 | $47,011,000 | $-3,162,000 | $-97,248,000 |
| Per Share | ||||
| Diluted EPS | $-3.47 | $1.68 | $-0.20 | $-3.02 |
| Basic EPS | $-3.47 | $1.76 | $-0.20 | $-3.02 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-153,802,000 | $50,784,000 | $-321,000 | $-95,353,000 |
| Reconciled Depreciation | $4,096,000 | $3,773,000 | $2,841,000 | $1,895,000 |
| EBITDA (Bullshit earnings) | $-153,802,000 | $50,784,000 | $-321,000 | $-95,353,000 |
| EBIT | $-157,898,000 | $47,011,000 | $-3,162,000 | $-97,248,000 |
| Diluted Average Shares | $41,371,486 | $39,003,169 | $33,050,319 | $31,293,312 |
| Basic Average Shares | $41,371,486 | $37,306,363 | $33,050,319 | $31,293,312 |
| Diluted NI Availto Com Stockholders | $-143,750,000 | $65,626,000 | $-6,685,000 | $-94,616,000 |
| Tax Provision | $924,000 | $859,000 | $18,741,000 | $0 |
| Research And Development | $142,269,000 | $125,306,000 | $99,884,000 | $66,609,000 |
| Selling General And Administration | $41,050,000 | $38,465,000 | $32,291,000 | $30,639,000 |
| Other Gand A | $41,050,000 | $38,465,000 | $32,291,000 | $30,639,000 |
Fetched: 2026-06-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $306,133,000 | $428,678,000 | $242,360,000 | $212,554,000 |
| Total Assets | $377,378,000 | $526,321,000 | $469,192,000 | $252,056,000 |
| Total Non Current Assets | $71,126,000 | $86,282,000 | $99,421,000 | $42,181,000 |
| Other Non Current Assets | $3,362,000 | $4,234,000 | $6,740,000 | $9,160,000 |
| Current Assets | $306,252,000 | $440,039,000 | $369,771,000 | $209,875,000 |
| Other Current Assets | $8,719,000 | $16,361,000 | $11,924,000 | $21,163,000 |
| Restricted Cash | $658,000 | $0 | - | - |
| Receivables | $1,177,000 | $3,680,000 | $5,878,000 | $0 |
| Other Receivables | $1,177,000 | $3,680,000 | $5,878,000 | - |
| Cash Cash Equivalents And Short Term Investments | $295,698,000 | $419,998,000 | $351,969,000 | $188,712,000 |
| Cash And Cash Equivalents | $90,394,000 | $101,211,000 | $67,602,000 | $45,157,000 |
| Cash Equivalents | - | $100,711,000 | $67,102,000 | $44,907,000 |
| Cash Financial | - | $500,000 | $500,000 | $250,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $50,932,000 | $59,207,000 | $68,230,000 | $25,936,000 |
| Long Term Debt And Capital Lease Obligation | $46,794,000 | $51,648,000 | $60,321,000 | $17,530,000 |
| Current Debt And Capital Lease Obligation | $4,138,000 | $7,559,000 | $7,909,000 | $8,406,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $71,245,000 | $97,643,000 | $226,832,000 | $39,502,000 |
| Total Non Current Liabilities Net Minority Interest | $46,794,000 | $58,161,000 | $68,036,000 | $17,530,000 |
| Non Current Deferred Liabilities | $0 | $6,513,000 | $7,715,000 | $0 |
| Current Liabilities | $24,451,000 | $39,482,000 | $158,796,000 | $21,972,000 |
| Other Current Liabilities | $1,174,000 | $1,039,000 | $1,004,000 | $431,000 |
| Current Deferred Liabilities | $342,000 | $13,654,000 | $132,261,000 | $0 |
| Payables And Accrued Expenses | $10,752,000 | $9,839,000 | $10,962,000 | $8,072,000 |
| Payables | $2,289,000 | $4,926,000 | $7,301,000 | $5,990,000 |
| Total Tax Payable | $0 | $667,000 | $4,024,000 | $0 |
| Income Tax Payable | $0 | $667,000 | $4,024,000 | $0 |
| Accounts Payable | $2,289,000 | $4,259,000 | $3,277,000 | $5,990,000 |
| Equity | ||||
| Common Stock Equity | $306,133,000 | $428,678,000 | $242,360,000 | $212,554,000 |
| Total Equity Gross Minority Interest | $306,133,000 | $428,678,000 | $242,360,000 | $212,554,000 |
| Stockholders Equity | $306,133,000 | $428,678,000 | $242,360,000 | $212,554,000 |
| Gains Losses Not Affecting Retained Earnings | $652,000 | $-43,000 | $195,000 | $-2,057,000 |
| Other Equity Adjustments | $652,000 | $-43,000 | $195,000 | $-2,057,000 |
| Retained Earnings | $-273,094,000 | $-129,344,000 | $-194,970,000 | $-188,285,000 |
| Other | ||||
| Ordinary Shares Number | $38,284,221 | $37,574,538 | $33,437,296 | $31,394,767 |
| Share Issued | $38,284,221 | $37,574,538 | $33,437,296 | $31,394,767 |
| Tangible Book Value | $306,133,000 | $428,678,000 | $242,360,000 | $212,554,000 |
| Invested Capital | $306,133,000 | $428,678,000 | $242,360,000 | $212,554,000 |
| Working Capital | $281,801,000 | $400,557,000 | $210,975,000 | $187,903,000 |
| Capital Lease Obligations | $50,932,000 | $59,207,000 | $68,230,000 | $25,936,000 |
| Total Capitalization | $306,133,000 | $428,678,000 | $242,360,000 | $212,554,000 |
| Additional Paid In Capital | $578,571,000 | $558,061,000 | $437,132,000 | $402,893,000 |
| Capital Stock | $4,000 | $4,000 | $3,000 | $3,000 |
| Common Stock | $4,000 | $4,000 | $3,000 | $3,000 |
| Non Current Deferred Revenue | $0 | $6,513,000 | $7,715,000 | $0 |
| Long Term Capital Lease Obligation | $46,794,000 | $51,648,000 | $60,321,000 | $17,530,000 |
| Current Deferred Revenue | $342,000 | $13,654,000 | $132,261,000 | $0 |
| Current Capital Lease Obligation | $4,138,000 | $7,559,000 | $7,909,000 | $8,406,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $8,045,000 | $7,391,000 | $6,660,000 | $5,063,000 |
| Current Accrued Expenses | $8,463,000 | $4,913,000 | $3,661,000 | $2,082,000 |
| Net PPE | $67,764,000 | $82,048,000 | $92,681,000 | $33,021,000 |
| Accumulated Depreciation | $-9,934,000 | $-9,424,000 | $-5,923,000 | $-3,301,000 |
| Gross PPE | $77,698,000 | $91,472,000 | $98,604,000 | $36,322,000 |
| Leases | $187,000 | $1,932,000 | $1,859,000 | $1,859,000 |
| Other Properties | $74,879,000 | $86,806,000 | $94,086,000 | $33,675,000 |
| Machinery Furniture Equipment | $2,632,000 | $2,734,000 | $2,659,000 | $204,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $205,304,000 | $318,787,000 | $284,367,000 | $143,555,000 |
| Construction In Progress | - | - | $0 | $584,000 |
| Treasury Shares Number | - | - | - | - |
Fetched: 2026-06-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-129,553,000 | $-44,715,000 | $134,189,000 | $-96,673,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-128,512,000 | $-41,557,000 | $139,803,000 | $-93,786,000 |
| Cash Flow From Continuing Operating Activities | $-128,512,000 | $-41,557,000 | $139,803,000 | $-93,786,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,041,000 | $-3,158,000 | $-5,614,000 | $-2,887,000 |
| Investing Cash Flow | $116,808,000 | $-27,798,000 | $-138,395,000 | $-148,650,000 |
| Cash Flow From Continuing Investing Activities | $116,808,000 | $-27,798,000 | $-138,395,000 | $-148,650,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $99,608,000 | $19,407,000 | $0 |
| Financing Cash Flow | $887,000 | $102,964,000 | $21,037,000 | $479,000 |
| Cash Flow From Continuing Financing Activities | $887,000 | $102,964,000 | $21,037,000 | $479,000 |
| Net Common Stock Issuance | $0 | $99,608,000 | $19,407,000 | $0 |
| Common Stock Issuance | $0 | $99,608,000 | $19,407,000 | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Income Tax Paid Supplemental Data | $1,699,000 | $4,622,000 | $14,717,000 | $0 |
| End Cash Position | $94,344,000 | $105,161,000 | $71,552,000 | $49,107,000 |
| Beginning Cash Position | $105,161,000 | $71,552,000 | $49,107,000 | $291,064,000 |
| Changes In Cash | $-10,817,000 | $33,609,000 | $22,445,000 | $-241,957,000 |
| Proceeds From Stock Option Exercised | $887,000 | $3,356,000 | $1,630,000 | $479,000 |
| Net Investment Purchase And Sale | $117,849,000 | $-24,640,000 | $-132,781,000 | $-145,763,000 |
| Sale Of Investment | $259,462,000 | $413,077,000 | $274,426,000 | $76,214,000 |
| Purchase Of Investment | $-141,613,000 | $-437,717,000 | $-407,207,000 | $-221,977,000 |
| Net PPE Purchase And Sale | $-1,041,000 | $-3,158,000 | $-5,614,000 | $-2,887,000 |
| Purchase Of PPE | $-1,041,000 | $-3,158,000 | $-5,614,000 | $-2,887,000 |
| Change In Working Capital | $-4,796,000 | $-118,853,000 | $136,315,000 | $-11,111,000 |
| Change In Other Working Capital | $-19,825,000 | $-119,809,000 | $139,976,000 | - |
| Change In Other Current Liabilities | $-8,275,000 | $-9,023,000 | $-11,862,000 | $-7,451,000 |
| Change In Other Current Assets | $10,883,000 | $12,876,000 | $426,000 | $3,313,000 |
| Change In Payables And Accrued Expense | $2,276,000 | $-658,000 | $5,031,000 | $7,049,000 |
| Change In Accrued Expense | $4,742,000 | $1,708,000 | $3,812,000 | $1,762,000 |
| Change In Payable | $-2,466,000 | $-2,366,000 | $1,219,000 | $5,287,000 |
| Change In Account Payable | $-1,799,000 | $991,000 | $-2,805,000 | $5,287,000 |
| Change In Tax Payable | $-667,000 | $-3,357,000 | $4,024,000 | $0 |
| Change In Income Tax Payable | $-667,000 | $-3,357,000 | $4,024,000 | $0 |
| Change In Prepaid Assets | $7,642,000 | $-4,437,000 | $8,622,000 | $-14,022,000 |
| Change In Receivables | $2,503,000 | $2,198,000 | $-5,878,000 | $0 |
| Stock Based Compensation | $19,609,000 | $17,915,000 | $13,111,000 | $9,895,000 |
| Amortization Of Securities | $-3,671,000 | $-10,018,000 | $-5,779,000 | $151,000 |
| Depreciation Amortization Depletion | $4,096,000 | $3,773,000 | $2,841,000 | $1,895,000 |
| Depreciation And Amortization | $4,096,000 | $3,773,000 | $2,841,000 | $1,895,000 |
| Depreciation | $4,096,000 | $3,773,000 | $2,841,000 | $1,895,000 |
| Net Income From Continuing Operations | $-143,750,000 | $65,626,000 | $-6,685,000 | $-94,616,000 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
Fetched: 2026-06-14